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Low-density lipoprotein receptor (LDLR) is a cell-
surface receptor that plays a central role in regulating
cholesterol levels. Increased levels of LDLR would
lead to reduced cholesterol levels and contribute to
strategies designed to treat hypercholesterolemia.
We have previously shown that duplex RNAs com-
plementary to transcription start sites can associate
with noncoding transcripts and activate gene expres-
sion. Here we show that duplex RNAs complemen-
tary to the promoter of LDLR activate expression of
LDLRand increase thedisplayof LDLRon the surface
of liver cells. Activation requires complementarity to
the LDLR promoter and can be achieved by chemi-
cally modified duplex RNAs. Promoter-targeted
duplex RNAs can overcome repression of LDLR
expression by 25-hydroxycholesterol and do not
interfere with activation of LDLR expression by lova-
statin. These data demonstrate that small RNAs can
activate LDLR expression and affect LDLR function.
INTRODUCTION
The ability of small RNAs to inhibit gene expression by targeting
mRNA is well established (Siomi and Siomi, 2009). Several
reports have also appeared suggesting that small RNAs com-
plementary to gene promoters can also regulate gene expres-
sion. These antigene RNAs (agRNAs) (we use this terminology
to distinguish them from RNAs complementary to mRNA)
can either inhibit (Morris et al., 2004; Ting et al., 2005; Janowski
et al., 2005; Janowski et al., 2006; Kim et al., 2006; Han et al.,
2007; Janowski et al., 2007; Napoli et al., 2009; Hawkins et al.,
2009; Watts et al., 2010b; Yue et al., 2010) or activate gene
expression (Li et al., 2006; Janowski et al., 2007; Morris et al.,
2008; Place et al., 2008; Huang et al., 2010; Watts et al.,
2010b; Yue et al., 2010). Argonaute 2 (AGO2), a key protein
involved in RNAi (Siomi and Siomi, 2009), has been reported to
be required for gene activation (Li et al., 2006; Morris et al.,
2008; Chu et al., 2010), and both AGO2 and a related protein,
AGO1, have been implicated in transcriptional silencing (Janow-1344 Chemistry & Biology 17, 1344–1355, December 22, 2010 ª2010ski et al., 2006; Kim et al., 2006; Napoli et al., 2009; Chu et al.,
2010). RNA-directed transcriptional gene silencing in human
cells has been recently reviewed (Morris, 2009; Pastori et al.,
2010).
Gene silencing by double-stranded RNAs complementary to
mRNA has rapidly moved from being a laboratory tool to
a drug development strategy with several ongoing clinical trials
(Watts and Corey, 2010). Disease targets span a wide range
including viral infections, asthma, macular degeneration, and
cancer. Some RNA drugs are delivered locally by intraocular or
inhaled administration, whereas others are delivered systemi-
cally. Activation by RNA would supplement RNA-mediated
gene silencing and broaden the pool of genes susceptible to
therapeutic regulation by nucleic acids.
Our goal in this study was to examine how RNA-mediated
gene activation could be used to enhance expression of a thera-
peutically significant gene. We used the following criteria for
choosing a gene target: (1) there should be experimental or
clinical data showing that enhanced expression of the target
gene leads to a potentially favorable therapeutic outcome; and
(2) the target gene should be expressed in the liver, an organ
demonstrated to be accessible using current technology for
in vivo RNA delivery (Soutschek et al., 2004; Wolfrum et al.,
2007).
We chose the LDL receptor (LDLR) as a target for agRNAs.
LDLR is a cell-surface receptor responsible for internalization
of plasma LDL-cholesterol (LDL-c) (Goldstein and Brown,
2009). LDLR is expressed in almost all tissues, but liver is an
important organ for uptake of plasma LDL-c, 70% of which is
removed in liver. Enhanced expression of hepatic LDLR
decreases the level of plasma LDL-c, providing a strategy for
treatment of hypercholesterolemia.
Although statins, inhibitors for 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, have been widely used for
lowering levels of plasma LDL-c, the response to statin treatment
for lowering LDL-c varies due to genetic differences or other
factors in each patient (Chasman et al., 2004; Voora et al.,
2008). Therefore developing methods to increase the amount
of LDLR expression might broaden therapeutic options. Propro-
tein convertase subtilisin/kexin type 9 (PCSK9) is one promising
target whose expression is correlated with reduced levels of
LDLR (Horton et al., 2009). Antisense oligonucleotides (Graham
et al., 2007; Gupta et al., 2010) or duplex siRNAs (Frank-Kame-
nestsky et al., 2008) that reduce PCSK9 expression have beenElsevier Ltd All rights reserved
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Figure 1. Transcripts at the LDLR Promoter
(A) Location of gene specific primers used in rapid amplification of cDNA ends (RACE).
(B) Analysis of RACE products defining the 50 termini of LDLR mRNA. Primer + 10836 and primer + 10793 are gene specific primers complementary to exon 2 in
LDLR mRNA. Positive control is a product (900 base pairs) from a RACE using HeLa RT template and a control primer specific for b-actin cDNA.
(C) Analysis of 50 and 30 RACE products for sense or antisense noncoding transcripts. Nested PCRs were performed to increase specificity in amplification of
target cDNAs. Gene specific primers used in the 1st/2nd(nested) PCRs are shown on top of each lane.
(D) Relative locations of LDLR mRNA and the antisense transcript.
(E) Relative expression levels of LDLRmRNA and the antisense transcript evaluated by qRT-PCR. ***p < 0.001 (unpaired t test). Error shown is standard deviation
(SD). The transcription start sites and the 30 ends identified by these RACE analyses are shown in Figures S1A–S1C. Results showing the connection between the
50 and 30 RACE products are presented in Figure S1D. The sequence of the antisense transcript is shown in Figure S1E.
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RNA-Mediated Activation of LDLR Expressionshown to enhance LDLR expression by 2–3-fold and both types
of nucleic acid are currently in preclinical development.
The LDLR gene is located on chromosome 19 (19p13.2) and its
regulation has been well characterized (Su¨dhof et al., 1987;
Dawson et al., 1988; Smith et al., 1990; Briggs et al., 1993). The
promoter contains three imperfect repeats and two TATA-like
sequences. The transcription factor Sp1 binds to repeat 1 and
3, and sterol regulatory element binding proteins (SREBPs) bind
to repeat 2. Transcriptional activity is controlled by a feedback
mechanism through the processing of SREBPs and is negatively
regulated by sterols. LDLR protein is glycosylated in the
endoplasmatic reticulum (ER), generating LDLR precursor with
an apparent molecular weight of 120 kDa. The precursor is
subject to further glycosylation in the Golgi to be converted into
mature LDLR with an apparent molecular weight of 160 kDa
(Cummings et al., 1983). The mature LDLR is located on the cell
surface and plays a role in uptake of LDL-c through endocytosis.
We find that LDLR expression can be enhanced by addition
of small RNAs targeting the LDLR promoter. Levels of cell-Chemistry & Biology 17, 1344–135surface LDLR increase and the enhancement of LDLR expres-
sion is similar to that achieved by the cholesterol-lowering drug
lovastatin.
RESULTS
Characterization of Transcripts at the LDLR Promoter
Designing RNAs to target gene promoters requires an accurate
identification of the transcription start site. We used rapid ampli-
fication of cDNA ends (RACE) to analyze start sites for LDLR
mRNA in HepG2 cultured human liver cells (Figures 1A and 1B;
see Table S1 available online). After sequencing 69 clones, we
identified 14 transcription start sites for LDLR mRNA, and
the +1 transcription start site was designated based on our 50
RACE analysis and 50 EST data from the database for transcrip-
tion start sites (DBTSS: http://dbtss.hgc.jp/) (Figure S1A).
In previous studies of agRNA-mediated modulation of gene
expression, we examined expression of progesterone receptor
(PR). We observed that, rather than recognize chromosomal5, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1345
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Figure 2. Identification and Characterization of agRNAs that Activate LDLR Expression
(A) Location of target sites for agRNAs relative to the +1 transcription start site for LDLR.
(B) Western analysis showing the effects of varied agRNAs (50 nM) on expression of LDLR in HepG2 cells.
(C) Quantitation of results shown in (B) and independent replicates (n = 4). Statistical significance relative to mismatch control LDLRmm1 was tested by paired t
test. *p < 0.05; **p < 0.01; ***p < 0.001.
(D) Western blots showing a dose response for LDLR-24(U/U).
(E) Western blots showing a time course of LDLR expression after treatment with LDLR-24(U/U) (50 nM).
(F) ChIP of RNAP II using an anti-RNAP II antibody after treatment with activating agRNAs or mismatch control (50 nM). n = 3. Data were analyzed using Dunnett’s
test. **p < 0.01 relative to mismatch control LDLRmm1.
(G) RIP of AGO1 or AGO2 using an anti-AGO1 or anti-AGO2 antibody after treatment with activating agRNAs or mismatch control (50 nM). Error shown is SD. See
also Figure S2 and Figure S5.
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RNA-Mediated Activation of LDLR ExpressionDNA, agRNAs recognize noncoding transcripts that overlap the
PR gene promoter (Schwartz et al., 2008). The noncoding
transcript at the PR promoter was an antisense transcript
synthesized in a direction opposite to that of PR mRNA.
To investigate whether noncoding transcripts are expressed in
the LDLR promoter, we performed 50 and 30 RACE using LDLR
promoter-specific primers. We discovered a1450-nt antisense
transcript that overlaps the LDLR promoter, initiating at +880
and terminating at 570 (Figures 1C and 1D; Figures S1B–
S1E). This transcript is polyadenylated, unspliced, and ex-1346 Chemistry & Biology 17, 1344–1355, December 22, 2010 ª2010pressed at levels 90-fold below LDLR mRNA (Figure 1E). We
did not detect sense transcripts overlapping the LDLR promoter,
making the antisense transcript the most plausible target for
anti-LDLR agRNAs.
Design of agRNAs
The agRNAs used in these studies were 19-base pair RNA
duplexes with 2-base deoxythymidine overhangs at the 30 ends
(Table S2). The agRNAs were designed to be complementary to
sequences throughout the promoter for LDLR (Figure 2A). agRNAElsevier Ltd All rights reserved
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RNA-Mediated Activation of LDLR Expressionnomenclature is defined by the most upstream base. For
example, LDLR-24 would target bases 24 to 6 relative to
the +1 transcription start site for LDLR. LDLR+807 is a siRNA
complementary to LDLR mRNA. It represses LDLR expression
through the standard post-transcriptional RNAi mechanism and
we used it as a positive control for evaluating transfection effi-
ciency. Mismatch-containing dsRNAs LDLRmm1 and LDLRmm2
were designed based on the sequences of LDLR-24 and LDLR-
28, respectively.
Activation of LDLR Expression by agRNAs
We transfected agRNAs into HepG2 cells and evaluated expres-
sion of LDLR protein by western blotting 4 days later. RNAs were
transfected at 50 nM, a concentration chosen to combine
maximal efficacy with minimal toxicity to cells. Western analysis
revealed two immunoreactive bands due to the precursor and
mature forms of LDLR described above. agRNAs LDLR-24,
LDLR-28, and LDLR-15 increased LDLR protein levels by 2–3-
fold (Figures 2B and 2C). Enhanced expression was dose-
dependent and transient, reaching a maximum level 4 days after
transfection (Figures 2D and 2E; Figures S2A and S2B). Activa-
tion of LDLR expression by LDLR-24 and LDLR-28 was charac-
terized by potencies (EC50 values) of 26 and 16 nM, respectively
(Figure S5).
Consistent with the gene activation at the level of protein,
chromatin immunoprecipitation (ChIP) revealed 1.5- to 2-fold
elevation of levels of RNA polymerase II (RNAP II) at the LDLR
promoter (Figure 2F). Levels of the antisense transcript did not
decrease after transfection of activating agRNAs (Figure S2C),
suggesting that cleavage of the transcript by AGO2 does not
appear to be a primary cause of the activation. We also
monitored levels of H3K27 trimethylation (H3K27me3), which is
a transcription-suppressive chromatin mark. Unlike our previous
observation in activating agRNAs for PR (Yue et al., 2010), no
significant changes were detected for the chromatin mark (Fig-
ure S2D). This might reflect that H3K27me3 is not a dominant
regulatory factor for LDLR gene in HepG2 cells where basal
expression level of the gene is relatively high.
To check cell specificity of LDLR activation by agRNAs,
LDLR-24 and LDLR-28 were also tested in three other cell lines
including HuH-7, fibroblast cells (GM04281), and SW480.
Weobserved a similar effect of the oligomers on LDLRexpression
in the cell lines except for LDLR-24 in HuH-7 cells (Figure S2E).
When mismatch duplex RNAs were added, LDLR expression
started to decrease 4–5 days after transfection (Figures S3H
and S3I), probably due to a cellular response to the conditions
where cholesterol is less required as cells become confluent.
Thus the activation we observe runs counter to a natural
tendency of LDLR expression to decrease over time.
There are four AGO proteins in mammalian cells (Siomi and
Siomi, 2009). AGO2 is the ‘‘catalytic engine’’ that drives mRNA
cleavage (Liu et al., 2004; Meister et al., 2004; Rand et al.,
2004), whereas the roles of AGO1, AGO3, and AGO4 are less
well known. We and others have previously reported that the
action of promoter-targeted RNAs involves AGO1 or AGO2
(Li et al., 2006; Kim et al., 2006; Janowski et al., 2006; Morris
et al., 2008; Napoli et al., 2009; Chu et al., 2010; Yue et al., 2010).
To determine whether AGO proteins might also be involved in
agRNA-mediated activation of LDLR, we performed RNA immu-Chemistry & Biology 17, 1344–135noprecipitation (RIP) for AGO1andAGO2 on addition of agRNAs.
Using RIP we observed primary recruitment of AGO2 to the
LDLR antisense transcript in cells treated with LDLR-24(U/U) or
LDLR-28(U/U) (Figure 2G). Recruitment of AGO1 could also
be detected but at lower levels. No PCR products were
amplified in the samples without reverse transcription, suggest-
ing that we were not detecting amplification of chromosomal
DNA.
Testing Mismatch-Containing or Randomly Scrambled
Oligomers
To evaluate whether sequence complementarity of agRNA to the
LDLR promoter is required for activation, we tested another nine
mismatch-containing or randomly scrambled RNA duplexes
based on the sequence of LDLR-24 or LDLR-28 in addition to
LDLRmm1 and LDLRmm2 (Figure 3A; Table S2). Mismatch-con-
taining RNAs were designed to spread mismatches throughout
the RNA or concentrate them in regions with potential seed
sequences. Seed sequences contain positions 2–8 within the
duplex RNA and complementarity between seed sequences
and RNA targets is known to be an important determinant for
successful RNAi.
With one exception, these control oligomers did not activate
LDLR expression (Figure 3B; Figure S3). The exception was
LDLRmm4 that contains three mismatches outside the seed
sequence predicted for recognition of the antisense transcript.
One explanation for activation by LDLRmm4 is that it preserves
the potential to form necessary seed sequence interactions with
the antisense transcript detected at the LDLR promoter. Consis-
tent with this hypothesis, RIP experiments for the mismatch
oligomers showed recruitment of AGO2 to the antisense tran-
script by active duplex LDLRmm4 that contained mismatches
outside the seed sequence, but not by inactive duplex
LDLRmm3 that contained mismatches disrupting the predicted
seed sequence (Figure S3J).
Several RNA duplexes, notably LDLR-65, LDLR-35, and
LDLR-18, appeared to reduce gene expression (Figures 2B
and 2C). However, we observed that some of the scrambled
oligomers induced nonsequence-specific silencing of LDLR
gene (Figure S3), complicating interpretation of LDLR gene
silencing by agRNAs. Because of the tendency toward nonspe-
cific silencing and our focus on gene activation, we did not inves-
tigate gene silencing further.
Effect of Chemical Modifications on Activation of LDLR
Development of duplex RNAs as drugs will require chemical
modifications to improve their stability, specificity, and potency
(De Paula et al., 2007; Watts et al., 2008). Modifying siRNAs
can reduce off-target effects resulting from the miRNA pathway
(Jackson et al., 2006), the innate immune system (Judge and
MacLachlan, 2008), or loading of the wrong strand (Bramsen
et al., 2007).
To determinewhether activation of LDLRwould be compatible
with chemical modifications commonly used during drug devel-
opment, we tested introducing 20-O-methyl or 20-fluoro nucleo-
tides into LDLR-24 or LDLR-28 (Figure 4A; Table S2). Each
type of modified duplex is assigned two uppercase letters. The
first letter describes the chemical modification of the sense
strand, whereas the second letter describes modification of the5, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1347
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Figure 3. Effect of Mismatch-Containing Duplexes on Expression of LDLR
(A) The sequences of LDLR-24(U/U), LDLR-28(U/U), and corresponding mismatch oligomers. The upper strands are sense strands and the lower strands are
antisense strands. Mismatch bases for LDLRmm1-6 are represented by red, bold face letters. Scrambled oligomers were generated by randomly scrambling
the sequence of LDLR-24 or LDLR-28.
(B) Western analyses of LDLR expression for LDLR-24(U/U), LDLR-28(U/U), mismatch-containing oligomers LDLRmm1-6, and Scr1-5 (50 nM). NT indicates no
treatment. Western blots are representative from at least three independent replicates for each experiment. See also Figure S3.
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RNA-Mediated Activation of LDLR Expressionantisense strand. For example, U/F would have an unmodified
sense strand and an antisense strand containing 20-fluoro
substitutions.
We observed activation of LDLR expression by chemically
modified duplexes containing 20-O-methyl or 20-fluoro RNA
(Figures 4B and 4C). Potencies (EC50 values) ranged from 4.1 to
38 nM (Figure S5). Maximal activation (Amax) was between 2.2-
and 3.3-fold. For LDLR-24, activation was achieved with 20-O-
methyl RNA on the antisense strand or with 20-fluoro RNA on
the sense strand. When variants of LDLR-28 were tested,
activation was observed regardless of whether the 20-O-methyl
or 20-fluoro modifications were on the sense or antisense strand.
The phenomenon that similar patterns of chemical modification
have different effects ongene activationwhen applied to different
sequences has been observed previously in chemically modified
agRNAs that activate PR expression (Watts et al., 2010b).
The dependence of activation on the concentration of agRNA
duplex was similar regardless of which modified agRNA was
used (LDLR-24(U/O), LDLR-24(F/U), LDLR-28(U/O), or LDLR-
28(F/U)) (Figure 4D; Figures S4A–S4C). Relative to unmodified
LDLR-24(U/U) (Figure 2E), activation of LDLR by modified1348 Chemistry & Biology 17, 1344–1355, December 22, 2010 ª2010LDLR-24(U/O) persisted for a longer period, with elevated
protein levels being observed until Day 6 after transfection
(Figure 4E). These data demonstrate that agRNA-mediated
activation of LDLR expression is compatible with chemical modi-
fications commonly used during development of duplex RNA
therapeutics.
Similar to our results for unmodified agRNAs, we did not
observe any significant changes in the antisense transcript levels
after treatment with chemically modified agRNAs (Figure S4D).
In ChIP experiments for RNAP II, 1.5-fold increase of RNAP II
was observed at the LDLR promoter (Figure S4E). These results
suggest that mechanism of the LDLR activation is conserved
between unmodified and modified oligomers.
Upregulation of Cell-Surface LDLR
To examine whether agRNA-mediated activation of LDLR
expression would lead to enhanced display of LDLR on the
cell-surface and greater binding of LDL particles to the recep-
tors, we performed LDL binding assay using 3,30-dioctadecylin-
docarbocyanine labeled LDL (DiI-LDL). After treating cells with
an activating agRNA or a mismatch control, the cells wereElsevier Ltd All rights reserved
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Figure 4. Effect of Chemical Modifications on RNA-Mediated Activation of LDLR
(A) Structures of 20-O-methyl RNA and 20-fluoro RNA.
(B) Effect of 20-O-methyl and 20-fluoromodifications on activation by LDLR-24 (50 nM). Representative western blots (top) and quantification of three independent
replicates (bottom) are shown.
(C) Effect of 20-O-methyl and 20-fluoromodifications on activation by LDLR-28 (50 nM). Representative western blots (top) and quantification of three independent
replicates (bottom) are shown.
(D) Western blots showing a dose response for LDLR-24(U/O).
(E) Western blots showing a time course profile of LDLR expression after treatment with LDLR-24(U/O) (50 nM) in HepG2 cells. Statistical significance relative to
mismatch control LDLRmm1 was evaluated by paired t test. *p < 0.05; **p < 0.01. Error shown is SD. See also Figure S4 and Figure S5.
Chemistry & Biology
RNA-Mediated Activation of LDLR Expressionincubated with DiI-LDL and binding of DiI-LDL to the cell-surface
was measured by fluorescence microscopy. We observed
increased fluorescence in cells treated with Dil-LDL after
addition of LDLR-24(U/U) relative to cells treated with the
mismatch control LDLRmm1 (Figure 5A). Addition of unlabeled
LDL quenched the fluorescence, indicating that the interaction
is specific.Chemistry & Biology 17, 1344–135Binding of DiI-LDL to the cell-surfacewas quantified using flow
cytometry. Cells treatedwith varying concentrations of activating
agRNAs or a mismatch control were incubated with DiI-LDL and
fluorescence from DiI-LDL bound to the cell-surface was
measured. We observed enhanced fluorescence from DiI-LDL
in LDLR-24(U/U)- or LDLR-28(U/U)-treated cells relative to
LDLRmm1-treatedcells inadose-dependentmanner (Figures5B5, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1349
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Figure 5. Binding of LDL to Cell Surface LDLR
(A) Fluorescent microscopy of HepG2 cells 4 days after transfection of LDLR-24(U/U) or LDLRmm1 (50 nM), or no treatment. Cells were treated with DiI-LDL
(12 mg/ml) or a mixture of DiI-LDL (12 mg/ml) and unlabeled LDL (120 mg/ml) at 4C for 2 hr.
(B) Flow cytometry showing DiI-LDL association. Varying concentrations of LDLR-24(U/U), LDLR-28(U/U), or LDLRmm1 were transfected into HepG2 cells.
Four days after transfection, cells were treated with DiI-LDL (12 mg/ml) at 4C for 2 hr and fluorescence from DiI-LDL bound to cells was measured by FACScan.
(C) Quantitation of cell surface-bound DiI-LDL after treatments shown in (B). Mean fluorescence value for no treatment sample was expressed as 100%.
Error shown is standard error of the mean (SEM); n = 5.
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NAs led to enhanced trafficking of LDL particles to cell surface.
Effect of agRNAs on Expression of Interferon
Responsive Genes
Some small RNAs can induce off-target effects through induc-
tion of the interferon response (Hornung et al., 2005; Birmingham
et al., 2006). This potential activity is important for studies with
LDLR because some cytokines have been reported to promote
enhanced LDLR expression and increased LDL binding in cells
(Stopeck et al., 1993; Ruan et al., 1998). To investigate involve-
ment of interferon response to LDLR activation by agRNAs, we
evaluated expression of interferon responsive genes by quanti-
tative reverse transcription-PCR (qRT-PCR) after transfection of
unmodified or modified agRNAs, LDLR-24(U/U), LDLR-24(U/O),1350 Chemistry & Biology 17, 1344–1355, December 22, 2010 ª2010LDLR-24(F/U), LDLR-28(U/U), LDLR-28(U/O), andLDLR-28(F/U).
These agRNAs yielded only small changes for levels of inter-
feron-responsive gene expression including OAS1, OAS2,
MX1, IFITM1, and ISGF3g (Figures 6A and 6B). Addition of poly-
inosinic-polycytidylic acid (poly I:C), a potent inducer of inter-
feron response, substantially increases interferon responsive
gene expression, but did not upregulate LDLR expression at
any concentrations tested in HepG2 cells (Figures 6C and 6D).
Taken together, these data suggest that gene activation by
LDLR-24, LDLR-28, and their chemically modified variants is
not due to induction of interferon-responsive genes.
Addition of agRNAs and 25-Hydroxycholesterol
The membrane-bound transcription factor SREBP binds to
a sterol regulatory element within the LDLR promoter andElsevier Ltd All rights reserved
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Figure 6. Effect of Treatment with Activating agRNAs or poly I:C on Expression of Interferon-Responsive Genes and LDLR
(A) Western analysis showing effect of activating agRNAs (50 nM) or poly I:C (100 ng/ml) on LDLR expression.
(B) qRT-PCR analysis showing effect of activating agRNAs or poly I:C on the expression of interferon responsive genes using cells examined in (A). n = 3.
(C) Western blots showing effect of poly I:C on LDLR expression.
(D) qRT-PCR analysis showing effect of poly I:C on the expression of interferon responsive genes using cells examined in (C). n = 3. Western blots are represen-
tative from three independent replicates. Error shown is SD.
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RNA-Mediated Activation of LDLR Expressiontriggers increased transcription of the LDLR gene (Brown and
Goldstein, 1997). 25-Hydroxycholesterol represses LDLR
expression by inhibiting the processing step that yields active
NH2-terminal fragments of SREBP (Adams et al., 2004). To
determine whether addition of agRNAs might override this
repression and permit enhanced LDLR expression, we added
agRNA LDLR-24(U/U) or LDLR-28(U/U) in combination with
25-hydroxycholesterol.
We observed that LDLR-24(U/U) activated LDLR expression
regardless of whether 25-hydroxycholesterol was present.
Because treatment with 25-hydroxycholesterol lowers baseline
LDLR expression, the relative activation by anti-LDLR agRNAs
increased from 2–3-fold in cells grown under standard
conditions to 4–9-fold (Figure 7A). This result has practical
importance because, by suppressing basal expression,
agRNA-mediated activation can be observed more clearly.
Screening for activating agRNAs using cells treated to reduce
basal levels of gene activation may be a useful strategy for
more rapidly identifying the most promising agRNAs. Similar
increases of LDLR expression were achieved using chemically
modified agRNAs LDLR-24(U/O) and LDLR-28(F/U) in the pres-
ence of 25-hydroxycholesterol (Figure S6).Addition of agRNAs and Lovastatin
Lovastatin is an HMG-CoA reductase inhibitor whose adminis-
tration leads to increased levels of LDLR (Alberts, 1988). It is
a United States Food and Drug Administration (FDA)-approvedChemistry & Biology 17, 1344–135drug for lowering plasma LDL-c and comparing its activity
with agRNAs offers a useful metric for evaluating the potential
of agRNA-mediated modulation of LDLR expression. Addition
of agRNA LDLR-24(U/U) or lovastatin alone led to an similar
increase in expression of LDLR (Figure 7B). When we combined
lovastatin and LDLR-24(U/U) in HepG2 cells, LDLR levels were
significantly greater than when either agent was added individu-
ally, suggesting that the activities of lovastatin and anti-LDLR
agRNAs are additive.DISCUSSION
There are many strategies for using synthetic molecules to inter-
fere with the function of a protein or block its expression. Small
molecules can bind to protein targets and block their activity.
Largermolecules like duplex RNAs or antisense oligonucleotides
can bind tomRNA and reduce the levels of a target protein inside
cells. Molecules that selectively enhance the activity of a target
protein are more rare and their design poses a major challenge
for research at the interface of chemistry and biology.
One promising strategy for enhancing gene expression is
development of artificial transcription factors (Mapp and Ansari,
2007; Lee and Mapp, 2010). Several laboratories have reported
compounds that consist of a DNA binding domain and a -
transcriptional activation domain capable of recruiting transcrip-
tion factors (Stanojevic and Young, 2002; Kwon et al., 2004;
Liu et al., 2005; Xiao et al., 2007; Buhrlage et al., 2009). These5, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1351
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Figure 7. Combination Treatment of Activating agRNAs and 25-Hydroxycholesterol or Lovastatin
Fifty nanomolar duplex RNAs were used in these experiments.
(A) 25-Hydroxycholesterol (2 mM) or EtOH (vehicle) was added to cell culturemedia 2 days after transfection of activating agRNA LDLR-24(U/U), LDLR-28(U/U), or
amismatch oligomer LDLRmm1. Data shown arewestern blots of LDLR expression on day 4 (left) and quantitation of five independent replicates (right). Statistical
significance was evaluated by paired t test. *p < 0.05; ***p < 0.001 relative to mismatch control LDLRmm1.
(B) Lovastatin (10 or 30 mM) or EtOH (vehicle) was added to cell culture media 2 days after transfection of activating agRNAs or a mismatch oligomer. Data shown
are western blots of LDLR expression on day 4 (left) and quantitation of three independent replicates (right). Upregulation of LDLR expression by LDLR-24(U/U) or
lovastatin was statistically significant (two-way ANOVA; p < 0.01). No significant interaction effects were detected between the two different treatments using
agRNAs and lovastatin. NT indicates no treatment. Error shown is SD. See also Figure S6.
Chemistry & Biology
RNA-Mediated Activation of LDLR Expressionchemical approaches are simple and direct, but will require
optimization of cellular uptake, DNA binding, and gene activation
before activation at endogenous genes can be readily achieved
inside cells.
Synthetic small duplex RNAs designed to recognize
sequences at gene promoters provide an alternate strategy for
controlling gene expression. One advantage of activating small
RNAs is that several small RNAs are already being developed
in the clinic for gene silencing. The chemical and pharmacolog-
ical platform is, therefore, already well established. Activating
RNA has the potential to significantly extend the reach of RNA
to new targets for therapeutic development.
We find that duplex RNAs complementary to the LDLR
promoter increase LDLR expression by 2–3-fold. This increase
is comparable to the enhancement caused by treatment with
lovastatin, a pharmacologically useful regulator of LDLR expres-
sion. Previously, Chen et al. (2008) have reported that promoter-
targeted RNAs that yield RNA-mediated activation of p21
induced an antiproliferative effect in bladder cancer cells. These
two reports suggest that RNA-mediated gene activation can be
used to elevate expression of genes that are targets for thera-
peutic development.
We have previously shown that a promoter-associated anti-
sense transcript is involved in activation of PR and changed
abundance and/or localization of nuclear proteins such as1352 Chemistry & Biology 17, 1344–1355, December 22, 2010 ª2010hnRNP-k and HP1g in the PR promoter (Schwartz et al., 2008).
Activation of LDLR shares several similarities with activation of
PR: (1) the antisense transcript is the most plausible target; (2)
RNA Pol II is more abundant in the LDLR promoter after transfec-
tion of activating agRNAs; and (3) activating agRNAs recruit AGO
proteins to the antisense transcript in the cell nucleus. Other labs
have also reported similar recruitment of AGO to noncoding
transcripts at gene promoters (Han et al., 2007; Morris et al.,
2008; Hawkins et al., 2009; Napoli et al., 2009).
Data from our studies with agRNAs that target LDLR and PR
suggest that agRNAs modulate gene expression by recruiting
AGO2 protein to noncoding antisense transcripts at gene
promoters (Schwartz et al., 2008; Yue et al., 2010; Janowski
and Corey, 2010). This association occurs while the noncoding
transcript remains associated with the promoter. Because the
noncoding transcript is near promoter DNA, the AGO2/agRNA
complex can interact with the transcription and other regulatory
factors that normally control expression of PR or LDLR. A similar
mechanism has been proposed to explain RNA-mediated
epigenetic silencing in yeast (Grewal and Moazed, 2003).
The 2–3-fold increase in expression of LDLR protein, although
large enough to be physiologically relevant, is small, making
quantitative evaluation challenging. Relative to our previous
experience activating PR, where 25–50-fold increases in protein
levels were common, the smaller changes of LDLR expressionElsevier Ltd All rights reserved
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when basal levels of expression are reduced by addition of
25-hydroxycholesterol, the relative amount of activation
increases and fewer replicates are required. Screening for RNA
activators of other genes will be facilitated by assays using
conditions that reduce the basal level of target gene expression.
SIGNIFICANCE
We describe activation of LDLR by promoter-targeted
dsRNAs in cultured human liver cells. Our results show
that gene activation can be achieved for a target protein
known to be important for therapy of hypercholesterolemia
and yield functional enhancement of the cell-surface LDLR
in agRNA-treated cells. Chemically modified oligomers can
also activate LDLR expression, suggesting that the
approach of using activating agRNAs for therapeutic targets
is compatible with in vivo applications. We identified several
candidate agRNAs after screening a relatively small pool of
promoter-targeted dsRNAs. Therapeutic use of activating
agRNAs might provide an option for development of
RNA-based drugs.
EXPERIMENTAL PROCEDURES
RACE Analysis
RACE was performed using the GeneRacer Kit (Invitrogen). cDNA samples
from HepG2 cells were prepared according to the kit manufacturer’s protocol.
The 50 or 30 end of cDNA was amplified through two nested PCR steps using
Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and appropriate
primer sets (Table S1). The thermal cycling condition of the first PCR was:
94C for 2 min, followed by five cycles of 94C for 30 s and 72C for 1 min,
five cycles of 94C for 30 s and 70C for 1 min, and 25 cycles of 94C for
30 s, 66C for 30 s, and 68C for 1 min. The condition of the following nested
PCR was: 94C for 2 min, followed by 20 cycles of 94C for 30 s, 65C for 30 s,
and 68C for 1 min. After gel purification, the PCR products were cloned into
a pCR4-TOPO vector and sequenced (McDermott sequencing core, UT
Southwestern).
qRT-PCR
Total RNA was extracted using TRIzol (Invitrogen). RNA samples were treated
with DNase I (Worthington Biochemical) at 25C for 10 min and reverse tran-
scription was performed using High Capacity Reverse Transcription Kit
(Applied Biosystems) according to the manufacturer’s protocol. Quantitative
PCR (qPCR) was performed on a 7500 real-time PCR system (Applied Biosys-
tems) using iTaq SYBR Green Supermix (Bio-Rad). Primer sequences are
described in Table S1. Standard curves for each primer set were made to
evaluate primer efficiency in PCR amplification. qPCR data for comparing
expression levels of LDLRmRNA and the antisense transcript were normalized
by the difference in primer efficiency.
Cell Culture and Transfection
Unmodified, 20-O-methyl, and 20-fluoro RNAs with two 20-deoxythymidine
bases at the 30 end were obtained from Integrated DNA Technologies or Alny-
lam Pharmaceuticals. HepG2 (American Type Culture Collection (ATCC)) and
fibroblast cells (GM04281; Coriell) were cultured with Minimum Essential
Medium Eagle (MEM; Sigma) supplemented with 10% FBS, 1% MEM nones-
sential amino acids (Sigma), and 1 mM sodium pyruvate (Sigma). HuH-7
(Japanese Collection of Research Bioresources) and SW480 cells (ATCC)
were cultured with Dulbecco’s modified Eagle’s medium (Sigma) supple-
mented with 10% FBS and 1 mM sodium pyruvate. Cells were plated in
6-well plates at 120,000 (HepG2 and HuH-7), 60,000 (fibroblast), or 150,000
(SW480) cells/well 2 days before transfection. Duplex RNAs were transfected
into cells using Lipofectamine RNAiMAX (Invitrogen). Cationic lipid (2.4 ml forChemistry & Biology 17, 1344–13550 nMdsRNA)was added toOptiMEM (Invitrogen) containing oligonucleotides
and the oligonucleotide-lipid mixture (250 ml) was incubated at room temper-
ature for 20 min. OptiMEM (for HepG2 and fibroblast) or full media (for HuH-
7 and SW480) was added to a final volume of 1.25 ml and the mixture was
applied to cells. Media was exchanged 1 day later with fresh supplemented
media (2 ml).ChIP/RIP
HepG2 cells were seeded at 1,080,000 cells in 15 cm dishes 2 days before
transfection for ChIP or RIP experiments. Two dishes were treated with
activating agRNAs (LDLR-24[U/U] and LDLR-28[U/U]) or mismatch controls
(LDLRmm1, LDLRmm3, and LDLRmm4) (50 nM). Four days after transfection,
cells were crosslinked with 1% formaldehyde. Cells were recovered by
scraping and nuclei were isolated using hypotonic lysis buffer (5 ml; 10 mM
Tris-HCl [pH 7.5], 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40). Nuclei were lysed
in lysis buffer (1ml; 1%SDS, 10mMEDTA, 50mMTris-HCl [pH 8.1], 13Roche
protease inhibitors cocktail, 40 U/mL RNasin Plus RNase Inhibitor [Promega])
and sonicated (2 pulses, 20% power, 20 s).
The cell lysate (100 ml) was incubated overnight with antibodies in immuno-
precipitation buffer (1 ml; 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, and 13 Roche protease inhibitors
cocktail, 40 U/ml RNasin Plus RNase Inhibitor). Monoclonal anti-RNAP II
(2 mg; Millipore) and polyclonal anti-H3K27me3 (2 mg; Millipore) antibodies
were used for ChIP experiments. Polyclonal anti-AGO1 (2 mg; Millipore) and
polyclonal anti-AGO2 (2 mg; Millipore) antibodies were used for RIP experi-
ments. Normal mouse IgG (2 mg; Millipore) or normal rabbit IgG (2 mg; Millipore)
was used as a control. After the antibodies were recoveredwith 50 ml of Protein
G Plus/Protein A Agarose Beads (Calbiochem), the beads were washed with
1 ml of low salt (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
[pH 8.1], 150 mM NaCl), high salt (see low salt but with 500 mM NaCl), LiCl
solution (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, and
10 mM Tris-HCl [pH 8.1]), and TE buffer (pH 8.0). Protein was eluted twice
with 250 ml of elution buffer (1% SDS, 0.1 M NaHCO3, and 40 U/ml RNasin
Plus RNase Inhibitor) for 15 min at room temperature. Crosslinking was
reversed by adding NaCl to 200 mM and heating at 65C for at least 2 hr.
Protein was digested by incubating with Proteinase K (20 mg; Invitrogen) at
42C for 50 min, followed by phenol extraction using an equal volume of
phenol/chloroform/isoamyl alcohol. DNA/RNA in the aqueous layer was
precipitated using 1/10 volume 3 M sodium acetate (pH 5.5), 2.2 volumes
ethanol, and glycogen (40 mg; Sigma). For ChIP, the pellet was resuspended
in 80 ml of nuclease-free water. qPCR was performed using iTaq SYBR
Supermix and primers specific for the LDLR promoter (50-CCTGCTAGA
AACCTCACATTG-30; 50-GGATCACGACCTGCTGTGTC-30). For RIP, the pellet
was resuspended in 16 ml of nuclease-free water. After treating each sample
with DNase I at 25C for 10 min, reverse transcription reactions were per-
formed only for input and +RT samples. qPCR was performed using iTaq
SYBR Supermix and primers specific for the antisense transcript. PCR prod-
ucts were analyzed on 2.5% agarose gel and stained with ethidium bromide.Analysis of LDLR Protein Expression
Cells were harvested 4 days after transfection for western blotting analysis.
Cells were detached from plates using cell dissociation solution (Sigma) and
lysed with lysis buffer (50 mM Tris-HCl, 120 mM NaCl, 0.5% NP-40, 1 mM
EDTA, 1 mM DTT, and protease inhibitor [Calbiochem]). Protein concentra-
tions were quantified with BCA assay kit (Thermo Scientific). SDS-PAGE
was performed using 7.5% Tris-HCl gels (Bio-Rad). Gels were run at 100 V
for 60min. After gel electrophoresis, proteins were transferred to nitrocellulose
membrane (Hybond-C-Extra; GE Healthcare) at 100 V for 2 hr. After blocking
the membrane with 5% nonfat dry milk/TBST at room temperature for 1 hr,
the membrane was incubated with primary antibody specific for LDLR or
b-actin at the following dilution ratio: anti-LDLR antibody (ab52818;
1:10,000; Abcam), anti-b-actin antibody (1:20,000; Sigma). HRP-conjugated
anti-rabbit (1:10,000; Jackson ImmunoResearch) or anti-mouse (1:20,000;
Sigma) secondary antibody was used for visualizing proteins using SuperSig-
nal West Pico Chemiluminescent Substrate (Thermo Scientific). Protein bands
were quantified using ImageJ software.5, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1353
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agRNAs (50 nM) were transfected in HepG2 cells as described above (Day 0).
On day 4, cells were washed with cold PBS three times and then incubated
with DiI-LDL (12 mg/ml; Invitrogen) or DiI-LDL (12 mg/ml) + unlabeled LDL
(120 mg/ml; Invitrogen) in serum-free MEM at 4C for 2 hr. After the incubation,
cells were washed with cold PBS five times and then treated with 4% parafor-
maldehyde at room temperature for 25 min. After the fixation, cells were
washed with PBS twice. Cells were observed using fluorescence microscopy
(Zeiss Axiovert 200 M).
agRNAs (LDLR-24(U/U), LDLR-28(U/U), and LDLRmm1; 0, 25, 50, 100 nM)
were also transfected into HepG2 cells for flow cytometry experiments. Four
days after transfection, cells were harvested using cell dissociation solution
and washed with 1 ml of PBS. After filtering cells using cell strainers (40 mm;
BD Falcon), 250,000 cells in 250 ml of serum-free MEM were incubated with
DiI-LDL (3 mg) at 4C for 2 hr. Cells were collected by centrifugation
(2500 rpm, 5 min) and then washed three times with 1 ml of PBS containing
0.5% BSA and 0.02% sodium azide. The fluorescence of cell-associated
DiI-LDL was measured by FACScan (Becton Dickinson) with 10,000 cells
per sample.
Analysis of Interferon Responsive Genes
mRNA levels of the interferon responsive genes including OAS1, OAS2, MX1,
IFITM1, and ISGF3g were measured by qRT-PCR. agRNAs (50 nM) and Poly
I:C (0–100 ng/ml; Sigma) were transfected into HepG2 cells using the cationic
lipid as described above. Three days after transfection, total RNAs from
dsRNA-treated, poly I:C-treated, or untreated samples were isolated using
TRIzol. The RNAs were treated with DNase I at 25C for 10 min, followed by
reverse transcription reaction at 37C for 2 hr. qPCR was performed using
iTaq SYBR Supermix and primers specific for the interferon responsive genes
(Interferon Response Detection Kit; System Biosciences). LDLR protein levels
on day 4 were also measured by western blot analysis.
Combination Treatment with Lovastatin and agRNAs
Inactive lovastatin (17 mg; Sigma) in the lactone form was converted into its
active form as previously described (Morimoto et al., 2006). The stock solution
(5 mM in 5%EtOH) was stored at80C until use. dsRNAs (50 nM) were trans-
fected into HepG2 cells as described above (Day 0), and the media were
exchanged one day later. Two days after transfection, lovastatin (10 or
30 mM) or 5% EtOH solution (vehicle) was added to each dsRNA-treated cell
(final EtOH concentration: 0.03%). The cells were harvested on Day 4 for
western blot analysis.
Combination Treatment with 25-Hydroxycholesterol and agRNAs
dsRNAs (50 nM) were transfected into HepG2 cells as described above
(Day 0), and themedia were exchanged one day later. Two days after transfec-
tion, 25-hydroxycholesterol (2 mM; Sigma) dissolved in EtOH or EtOH only
(vehicle) was added to each dsRNA-treated cell (final EtOH concentration:
0.04%). The cells were harvested on Day 4 for western blot analysis.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and two tables, and can be
found with this article online at doi:10.1016/j.chembiol.2010.10.009.
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